Hubungan Neutrophil Lymphocyte Ratio, Platelet Lymphocyte Ratio, dan Ferritin dengan Pemberian Remdesivir pada Pasien Covid-19 dengan Peningkatan Transaminase
DOI:
https://doi.org/10.35790/ecl.v11i3.46845Abstract
Abstract: Remdesivir is used as the treatment for coronavirus disease 2019 (Covid-19). Moreover, its pharmacological effect has an impact on the improvement of inflammatory biomarkers. Neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), and ferritin are simple inflammation parameters that are widely available and can describe inflammation in Covid-19 patients. This cross-sectional study involved 52 Covid-19 patients at Prof. Dr. R. D. Kandou Hospital from March 2020 to March 2021. Blood tests were performed on the day before remdesivir administration and one week after administration. The results obtained a significant correlation between NLR and PLR with a value of r=0.641-0.670 (p<0.001) before and after administration of remdesivir. In all patients there was a decrease in ferritin with remdesivir administration (∆= -111.41). In conclusion, there are decreases in NLR, PLR and ferritin values in Covid-19 patients with increased transaminase after being treated with remdesivir, especially living patients.
Keywords: remdesivir; coronavirus disease 2019 (Covid-19); platelet lymphocyte ratio; neutrophil lymphocyte ratio; ferritin
Abstrak: Remdesivir termasuk dalam tatalaksana coronavirus disease 2019 (Covid-19). Efek farmakologik remdesivir juga berdampak terhadap perbaikan biomarker inflamasi. Neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), dan feritin merupakan parameter inflamasi sederhana yang banyak tersedia dan dapat menggambarkan inflamasi pada pasien Covid-19. Studi potong lintang ini menelaah 52 pasien Covid-19 di RSUP Prof. Dr. R. D. Kandou sejak Maret 2020 hingga Maret 2021. Pemeriksaan darah diambil pada hari sebelum pemberian remdesivir dan satu minggu setelah pemberian. Hasil penelitian mendapatkan korelasi bermakna antara NLR dan PLR dengan nilai r=0,641-0,670 (p<0,001) baik sebelum dan setelah pemberian remdesivir. Pada keseluruhan pasien terdapat penurunan ferritin dengan pemberian remdesivir (∆=-111,41). Simpulan penelitian ini ialah terdapat penurunan nilai NLR, PLR dan ferritin pada pasien Covid-19 setelah diberikan remdesivir terutama pasien hidup.
Kata kunci: remdesivir; coronavirus disease 2019 (Covid-19); platelet lymphocyte ratio; neutrophil lymphocyte ratio; feritin
References
Aiswarya D, Arumugam V, Dineshkumar T, Gopalakrishnan N, Lamech TM, Nithya G, et al. Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance. Kidney Int Rep. 2021;6(3):586–93.
Aleem A, Mahadevaiah G, Shariff N, Kothadia JP. Hepatic manifestations of COVID-19 and effect of remdesivir on liver function in patients with COVID-19 illness. Proc (Bayl Univ Med Cent). 2021;34(4):473–7.
Aly MM, Meshref TS, Abdelhameid MA, Ahmed SA, Shaltout AS, Abdel-Moniem AE, et al. Can hematological ratios predict outcome of COVID-19 patients? A multicentric study. J Blood Med. 2021;12:505–15.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 — Final Report. N Engl J Med. 2020;383(19):1813–26.
Biamonte F, Botta C, Mazzitelli M, Rotundo S, Trecarichi EM, Foti D, et al. Combined lymphocyte/ monocyte count, D-dimer and iron status predict COVID-19 course and outcome in a long-term care facility. J Transl Med. 2021;19(1):79.
Bzeizi K, Abdulla M, Mohammed N, Alqamish J, Jamshidi N, Broering D. Effect of COVID-19 on liver abnormalities: a systematic review and meta‐analysis. Sci Rep. 2021;11(1):10599.
Du M, Yang S, Liu M, Liu J. COVID-19 and liver dysfunction: Epidemiology, association and potential mechanisms. Clin Res Hepatol Gastroenterol. 2022;46(2):101793.
Ernawati A. Tinjauan kasus COVID-19 berdasarkan jenis kelamin, golongan usia dan kepadatan penduduk di Kabupaten Pati. Jurnal Litbang: Media Informasi Penelitian, Pengembangan dan IPTEK. 2021;17(2):131–46.
Hashem MK, Khedr EM, Daef E, Mohamed-Hussein A, Mostafa EF, Hassany SM, et al. Prognostic biomarkers in COVID-19 infection: value of anemia, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and D-dimer. Egypt J Bronchol. 2021;15(1):29.
Komariah N, Salbiah S, Nugroho BAA, Suliati S, Widiantari AD, Murtiani F. Ferritin level as independent predictor of Covid-19: a cross sectional study. J Prof Medika [Internet]. 2022 [cited 2023 Jan 2];16(1):55-8. Available from: https://ejournal.upnvj.ac.id/index.php/JPM/article/ view/4183
Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: Focus on severity and mortality. Front Public Health. 2020;8:152.
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. NEJM. 2021;384(9):795–807
Kaushal K, Kaur H, Sarma P, Bhattacharyya A, Sharma DJ, Prajapat M, et al. Serum ferritin as a predictive biomarker in COVID-19. A systematic review, meta-analysis and meta-regression analysis. J Crit Care. 2022;67:172–81.
Kerboua KE. NLR: A cost-effective nomogram to guide therapeutic interventions in COVID-19. Immunological Investigations. 2021;50(1):92–100.
Khan FI, Kang T, Ali H, Lai D. Remdesivir strongly binds to RNA-Dependent RNA polymerase, membrane protein, and main protease of SARS-CoV-2: Indication from molecular modeling and simulations. Front Pharmacol [Internet]. 2021 [cited 2023 Feb 6];12:710778. Available from: https://www.frontiersin.org/articles/10.3389/fphar.2021.710778.
Koval D, Konopkina L, Bielosludtseva K, Krykhtina M. Platelet-to-lymphocyte ratio (PLR) as a predictor of Covid-19 pneumonia progression. In: Respiratory infections and bronchiectasis [Internet]. European Respiratory Society; 2021 [cited 2023 Jan 2]. p. PA653. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.congress-2021.PA653.
Lala V, Zubair M, Minter DA. Liver Function Tests. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [cited 2023 Jan 4]. Available from: http://www.ncbi.nlm.nih.gov /books/NBK482489/
Mahardhika GS, Tedjamartrono TD, Zain H, Ismail E. Remdesivir for COVID-19 in Indonesia: a case series. Respir Sci. 2021;1(3):182–93.
Mahase E. Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial. BMJ. 2022;376:0573.
Moon AM, Barritt AS. Elevated liver enzymes in patients with COVID-19: Look, but not too hard. Dig Dis Sci. 2021;66(6):1767–9.
Nagarajan R. COVID-19 Severity and mortality among chronic liver disease patients: a systematic review and meta-analysis. Prev Chronic Dis [Internet]. 2022 [cited 2023 Feb 2];19:E53. Available from: https://www.cdc.gov/pcd/issues/2022/21_0228.htm.
Nasir M, Perveen RA, Murshed M, Nazneen R, Talha KA. Survival and biomarkers of COVID-19 patients treated with remdesivir and favipiravir in ICU during the peak of pandemic: a single center study in Bangladesh. JPRI. 2020;32(45):14–22.
Pascale GD, Cutuli SL, Carelli S, Xhemalaj R, Rosà T, Bello G, et al. Remdesivir plus dexamethasone in COVID-19: a cohort study of severe patients requiring high flow oxygen therapy or non-invasive ventilation. PLOS ONE. 2022;17(4):e0267038.
Radonjić T, Milićević O, Jovanović I, Zdravković M, Dukić M, Mandić OM, et al. Elevated transaminases as predictors of COVID-19 pneumonia severity. Medicina (Kaunas). 2022;58(7):842.
Remdesivir [Internet]. LiverTox: clinical and research information on drug-induced liver injury [Internet]. National Institute of Diabetes and Digestive and Kidney Diseases; 2022 [cited 2023 Feb 2]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564049/
Sabers AJ, Williams AL, Farley TM. Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection. BMJ Case Rep. 2020;13(10):e239210.
Sarkar S, Kannan S, Khanna P, Singh AK. Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: a systematic review and meta-analysis. J Med Virol. 2022;94(1):211–21.
Sarkar S, Khanna P, Singh AK. The impact of neutrophil-lymphocyte count ratio in COVID-19: a systematic review and meta-analysis. J Intensive Care Med. 2022;37(7):857–69.
Tuteja S, Yu Z, Wilson O, Chen HC, Wendt F, Chung CP, et al. Pharmacogenetic variants and risk of remdesivir-associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID-19. Clinical and Translational Science. 2022;15(8):1880–6.
Wadhawan I, Sarkar A, Garg B. Prospective evaluation of hematological indices in prognostication of COVID-19 infection in pregnant population. Journal of South Asian Federation of Obstetrics and Gynaecology (JSAFOG). 2022;14(4):356–60.
Zhai G, Li M, Wang Y, Wu J. Drug-induced liver disturbance during the treatment of COVID-19. Front Pharmacol [Internet]. 2021 [cited 2023 Feb 2];12:719308. Available from: https://www.frontiersin. org/articles/10.3389/fphar.2021.719308.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Linda W. A. Rotty, Decky Andrea, Fujiyanto Fujiyanto, Harlinda Haroen, Pearla Lasut, Cecilia Hendratta, Agung Nugroho, Efata Polii
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
COPYRIGHT
Authors who publish with this journal agree to the following terms:
Authors hold their copyright and grant this journal the privilege of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that permits others to impart the work with an acknowledgment of the work's origin and initial publication by this journal.
Authors can enter into separate or additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (for example, post it to an institutional repository or publish it in a book), with an acknowledgment of its underlying publication in this journal.
Authors are permitted and encouraged to post their work online (for example, in institutional repositories or on their website) as it can lead to productive exchanges, as well as earlier and greater citation of the published work (See The Effect of Open Access).
